On this page
What is Fibromuscular Dysplasia?
Fibromuscular dysplasia (FMD) is a non-inflammatory, non-atherosclerotic disease that affects the walls of medium-sized arteries, progressively causing dangerous stenosis (narrowing) of varying severity in the majority of cases.
The prevalence of fibromuscular dysplasia in the general population is relatively low, and both its causes and the underlying mechanisms of vascular damage are still subjects of ongoing research. One of the most distinctive features of this condition is that the arterial wall damage is caused neither by an inflammatory process nor by cholesterol deposits on the vessel wall. This sets it apart from atherosclerosis, which is a far more common condition in the general population.
The natural history of fibromuscular dysplasia typically involves stable lesions over time, but with a notable potential for progression and the development of new symptoms, even many years after the initial onset (in approximately 30% of cases).
The clinical presentation varies depending on which arterial district is affected. Among the most common symptoms are:
- Elevated blood pressure
- Migraine and headache
- Lower back pain, abdominal pain, or limb pain
- Presyncope or syncope (near-fainting or loss of consciousness)
- General malaise and fatigue
- Pulsatile tinnitus
- Non-specific neurological symptoms
It is also important to note that individuals living with fibromuscular dysplasia may independently develop atherosclerotic disease over the years. The coexistence of both conditions will naturally result in a more severe clinical picture, particularly in those who have had fibromuscular dysplasia for a long time.
Diagnosis relies on patient history, physical examination, and routine blood tests, but imaging studies play a fundamental role. These include color Doppler ultrasound, CT scan, and MRI. Angiography remains the gold standard for diagnosis, but due to its invasive nature it is reserved for selected cases.
Treatment involves pharmacological therapy to control symptoms (such as antihypertensive medications) and to prevent serious complications (using antiplatelet agents). In selected patients, interventional treatment may be required, either through endovascular procedures or traditional open surgery.
Causes
From an anatomopathological perspective, fibromuscular dysplasia can cause lesions in the walls of medium-caliber arteries, including:
- Stenosis (narrowing of the vascular lumen)
- Dilatations (such as aneurysms)
- Dissections (separation of the arterial wall layers)
- Tortuosity (abnormal curving or twisting of the vessel)
Although virtually all medium-sized arteries in the body can be affected, fibromuscular dysplasia tends to damage certain vessels more frequently than others.
The most common locations include:
- Renal arteries (in 70% of cases, unilaterally)
- Cerebral arteries
- Cervical arteries (particularly the carotids)
- Upper limb arteries
- Lower limb arteries
- Splanchnic arteries (less frequently)
- Coronary arteries (less frequently)
A stenosis or dissection (with subsequent hemorrhage) of an artery leads to a significant reduction in blood supply to the organ it feeds, which then progressively suffers from ischemic damage. The reduction or cessation of organ function manifests as symptoms, ultimately resulting in fairly typical clinical presentations.
Classification
Blood vessel walls are composed of three superimposed layers (from the inside out):
- Tunica intima (innermost layer)
- Tunica media (middle layer)
- Tunica adventitia (outermost layer)
Stanley’s classification of fibromuscular dysplasia variants is based on which vascular layer is most affected by the disease:
- Medial fibromuscular dysplasia (the most common, accounting for approximately 80% of cases)
- Intimal fibromuscular dysplasia
- Adventitial fibromuscular dysplasia
The medial form involves progressive destruction of smooth muscle cells, which are gradually replaced by inelastic fibrous tissue. On angiography, this creates a characteristic pattern called the “string of beads” sign, due to alternating areas of stenosis and dilatation (also called microaneurysms). This pattern is considered highly suggestive of fibromuscular dysplasia and assists clinicians in differentiating it from atherosclerotic disease.
Risk Factors
Fibromuscular dysplasia shows a clear prevalence in young individuals aged between 20 and 50 years and is significantly more common in females.
Risk factors associated with the development of fibromuscular dysplasia include:
- Hereditary genetic component (familial clustering has been reported)
- Smoking
- Connective tissue disorders, such as:
- Marfan syndrome
- Ehlers-Danlos syndrome
- Neurofibromatosis
The exact genetic mechanisms remain under investigation, but research suggests that both genetic predisposition and hormonal factors (given the strong female predominance) play a role in disease development.
Symptoms
Some people with fibromuscular dysplasia may remain completely asymptomatic for many years, with the condition discovered incidentally during imaging studies performed for other health concerns.
The clinical picture varies according to the location of the affected vessels, the severity of the lesions, and the degree of vascular compromise. Significant stenosis or dissection with hemorrhage intuitively leads to more severe symptoms and often life-threatening complications, particularly when involving the carotid arteries or cerebral vessels.
Renal Artery Involvement
One of the most frequently observed symptoms in fibromuscular dysplasia is hypertension, which results from stenosis of the renal arteries. This is typically classified as renovascular hypertension and is particularly notable in young patients (accounting for approximately 10% of all causes of hypertension in younger individuals). It differs from common essential hypertension, which predominantly affects adults and older individuals, usually from the age of 40-50 years onward.
Additional symptoms related to renal artery disease may include:
- Impaired kidney function, detectable through blood tests such as:
- Elevated creatinine
- Reduced estimated glomerular filtration rate (eGFR)
- Electrolyte imbalances (sodium, potassium, calcium)
- Kidney atrophy (reduction in kidney size proportional to functional decline)
- Lumbar pain in cases of acute ischemic or hemorrhagic renal events
Cervical and Cerebrovascular Involvement
Stenosis or lesions affecting medium-sized cervical arteries reduce cerebral blood flow and may produce:
- Migraine (typically one-sided initially, but may generalize)
- Pulsatile tinnitus synchronized with the heartbeat
- Auditory disturbances such as rushing or whooshing sounds
- Vascular bruits detectable on auscultation
- Vertigo
- Presyncope (near-fainting sensation)
- Syncope with loss of consciousness
- Acute and severe neck pain (characteristic of vascular dissection)
If fibromuscular dysplasia directly involves the cerebral arteries, symptoms become more severe and neurological in nature, including:
- Headache poorly responsive to common analgesics
- Nausea and vomiting
- General malaise
- Pulsating sensation in the head
- Sudden loss of consciousness with fall
- Neurological deficits (affecting speech, motor function, or balance) due to transient ischemic attacks (TIA), cerebral hemorrhage, or stroke
- Horner syndrome (characterized by ptosis, miosis, enophthalmos, and reduced facial sweating)
- In the most severe cases, death
Splanchnic and Abdominal Involvement
Less common are splanchnic localizations of fibromuscular dysplasia, referring to the vessels supplying abdominal organs. In such cases, gastrointestinal symptoms may develop, most notably postprandial abdominal pain caused by insufficient blood flow to the intestine during digestion (a condition known as intestinal angina or angina abdominis).
Limb Artery Involvement
When fibromuscular dysplasia affects medium-sized arteries of the upper or lower limbs, patients experience pain during physical exercise or even simple walking. This presentation is known as intermittent claudication, defined by pain that disappears at rest and recurs when muscular blood demand increases.
In cases of hemodynamically significant limb stenosis, a blood pressure difference between the two sides of the body may be detected during examination, often confirming the diagnostic suspicion.
Coronary Involvement
Although rare, fibromuscular dysplasia can affect the coronary arteries, which supply blood to the heart. In significant cases, patients may develop classic cardiac symptoms including chest pain, arrhythmias, and all clinical features consistent with an acute coronary event or myocardial infarction.
Diagnosis
The diagnostic process begins with a thorough patient history and careful physical examination.
Patient History (Anamnesis)
A detailed medical interview aims to reconstruct the patient’s recent and past clinical history. For fibromuscular dysplasia, key areas of inquiry include:
- Presence of underlying diseases, especially vascular or renal conditions
- History of hypertension, particularly in young individuals or first-degree relatives
- Connective tissue disorders in the patient or close relatives
- Current medications
- Known atherosclerosis
- Other risk factors, including smoking
Physical Examination
A comprehensive physical examination is essential even in the absence of obvious symptoms. Auscultation with a stethoscope is particularly valuable, as it may reveal vascular bruits over the renal, carotid, or abdominal regions, reflecting turbulent blood flow through narrowed arteries.
Blood pressure measurement is a fundamental component of every medical visit. In fibromuscular dysplasia, it may reveal:
- Blood pressure above 140/100 mmHg in cases of renal artery stenosis (renovascular hypertension), which tends to be more severe than benign essential hypertension
- Blood pressure differences between limbs, suggesting unilateral vascular stenosis in one extremity
Imaging Studies
The gold standard for diagnosis is angiography, which allows precise identification of stenoses, aneurysms, and dissections throughout the arterial system. However, due to its invasive nature, it is not the first-line investigation.
Preferred non-invasive imaging options include:
- Color Doppler ultrasound (first-line, minimally invasive)
- CT angiography (Angio-CT)
- MR angiography (Angio-MRI)
Both CT and MRI with vascular protocols offer high diagnostic accuracy and are typically performed after a suspicious or inconclusive ultrasound, particularly when clinical suspicion remains high. These represent second-level investigations.
In asymptomatic patients with a silent clinical picture, the diagnosis is often suspected incidentally based on imaging studies performed for unrelated health concerns, which further underscores the importance of radiological reporting attentiveness.
Treatment
The prognosis of fibromuscular dysplasia is generally favorable, particularly given the high prevalence of asymptomatic cases and patients who do not experience lesion progression. Nevertheless, it remains a condition that warrants careful follow-up and ongoing clinical monitoring due to the potential for serious complications.
Importantly, fibromuscular dysplasia lesions do not regress spontaneously over the natural course of the disease, although they may remain mild and asymptomatic for extended periods.
Treatment decisions depend on several factors:
- The severity of the lesions
- Their location
- The presence and nature of symptoms
The therapeutic goals may be:
Conservative Management
Conservative management involves no invasive intervention and focuses on:
- Pharmacological control of symptoms (such as antihypertensive medications and migraine therapy)
- Strict clinical follow-up to monitor lesion evolution over time
Antiplatelet Therapy
Given the endovascular nature of the disease, one of the most serious complications is arterial thrombosis with partial or complete vessel occlusion. To prevent this, antiplatelet therapy (most commonly low-dose aspirin, “Cardioaspirin”) is recommended for all confirmed cases. Antiplatelet agents are especially critical in the postoperative period following endovascular procedures or surgical interventions.
Endovascular Treatment
The endovascular approach involves minimally invasive techniques that are less traumatic than traditional open surgery. Percutaneous transluminal angioplasty (PTA) is also less costly and associated with lower patient morbidity.
The main indications for angioplasty include stenotic lesions of the renal arteries causing:
- Renovascular hypertension of recent onset in young patients
- Hypertension resistant to pharmacological therapy
- Hypertension posing high risk for serious complications
- Impaired renal function
In some cases, when angioplasty alone is insufficient, stent placement within the treated vessel can improve the therapeutic outcome.
Open Surgical Treatment
Traditional open surgery is typically reserved for cases involving large aneurysms and for situations where endovascular procedures have been ineffective or are contraindicated. Surgical techniques include arterial reconstruction, bypass grafting, and aneurysm repair.
As with all interventional procedures, the complication rate must not be underestimated. It stands at approximately 15% and may include:
- Arterial dissection with hemorrhage
- Ischemia or infarction of the affected organ
- Arterial perforation
Cardiovascular Risk Factor Control
Regardless of the treatment approach, controlling atherosclerosis risk factors is essential. Patients should be counseled on the importance of smoking cessation, blood sugar management in diabetes, blood pressure control, and dietary management of dyslipidemia. Addressing these factors helps slow the progression of vascular lesions associated with fibromuscular dysplasia and prevents the additive burden of atherosclerotic disease.
Sources and Bibliography
- Harrison’s Principles of Internal Medicine, Vol. 1-2 (17th Ed., McGraw Hill).
- MedScape - Fibromuscular Dysplasia
- Olin JW, Gornik HL, et al. “Fibromuscular Dysplasia: State of the Science and Critical Unanswered Questions”. Circulation. 2014;129(9):1048-1078.
- Persu A, et al. “Fibromuscular Dysplasia: Everything a Cardiologist Should Know”. European Heart Journal. 2019.
- European Society of Vascular Medicine (ESVM) Guidelines on Fibromuscular Dysplasia.
